Conclusions
In our study, performed in patients with severe Hemophilia A in
prophylactic treatment, platelet function was essentially normal and did
not change after the infusion of FVIII. The amount of total
microvesicles and those of platelet origin are significantly decreased
in patients with Hemophilia A compared to healthy subjects. The
administration of FVIII was accompanied with a lower amount of
microvesicles of endothelial origin, suggesting that FVIII treatment
does not increase the thrombotic risk in these patients. Our results do
not support the use of platelet aggregation studies in patients with
severe Hemophilia A.